U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07951320) titled 'Recaticimab Add-on to IL-17A Inhibitors in Plaque Psoriasis With Dyslipidemia and Secondary Loss of Response to IL-17A Inhibitors' on Nov. 16.
Brief Summary: This multicenter, randomized, double-blind, placebo-controlled trial evaluates recaticimab added to ongoing IL-17A inhibitor therapy in adults with plaque psoriasis, dyslipidemia, and secondary loss of response to their IL-17A inhibitor.
Participants receive recaticimab 150 mg or matching placebo every 4 weeks in addition to their existing IL-17A inhibitor. The primary endpoint is PASI75 response at Week 16.
Both groups receive recaticimab after the Week 16 assessments throug...